Skip to content
Cultural Foundation
Author:
Pyrotech Therapeutics
Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World’s First Selective GSDMD Inhibitor to Enter Clinical Development
September 1, 2026